HRP20211569T1 - Modificirana rna koja kodira vegf-a polipeptide, formulacije, i upotrebe koje se na njih odnose - Google Patents
Modificirana rna koja kodira vegf-a polipeptide, formulacije, i upotrebe koje se na njih odnose Download PDFInfo
- Publication number
- HRP20211569T1 HRP20211569T1 HRP20211569TT HRP20211569T HRP20211569T1 HR P20211569 T1 HRP20211569 T1 HR P20211569T1 HR P20211569T T HRP20211569T T HR P20211569TT HR P20211569 T HRP20211569 T HR P20211569T HR P20211569 T1 HRP20211569 T1 HR P20211569T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- preparation
- use according
- disease
- therapy
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 20
- 238000009472 formulation Methods 0.000 title claims 19
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 239000011258 core-shell material Substances 0.000 claims 1
- 210000003748 coronary sinus Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002612 dispersion medium Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims 1
- 229960002773 hyaluronidase Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000002479 lipoplex Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346979P | 2016-06-07 | 2016-06-07 | |
| US201662411091P | 2016-10-21 | 2016-10-21 | |
| US201662432005P | 2016-12-09 | 2016-12-09 | |
| PCT/US2017/036188 WO2017214175A1 (en) | 2016-06-07 | 2017-06-06 | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
| EP17734885.1A EP3464338B1 (en) | 2016-06-07 | 2017-06-06 | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211569T1 true HRP20211569T1 (hr) | 2022-01-21 |
Family
ID=59270113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211569TT HRP20211569T1 (hr) | 2016-06-07 | 2017-06-06 | Modificirana rna koja kodira vegf-a polipeptide, formulacije, i upotrebe koje se na njih odnose |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866475B2 (enExample) |
| EP (2) | EP3971204A1 (enExample) |
| JP (3) | JP6859369B2 (enExample) |
| KR (4) | KR102552543B1 (enExample) |
| CN (2) | CN109790207B (enExample) |
| AU (2) | AU2017277277B2 (enExample) |
| CA (1) | CA3026500A1 (enExample) |
| CY (1) | CY1124667T1 (enExample) |
| DK (1) | DK3464338T3 (enExample) |
| ES (1) | ES2895421T3 (enExample) |
| HR (1) | HRP20211569T1 (enExample) |
| HU (1) | HUE056055T2 (enExample) |
| IL (1) | IL263370A (enExample) |
| LT (1) | LT3464338T (enExample) |
| MA (1) | MA45172B1 (enExample) |
| MX (1) | MX2018015110A (enExample) |
| PL (1) | PL3464338T3 (enExample) |
| PT (1) | PT3464338T (enExample) |
| RS (1) | RS62556B1 (enExample) |
| RU (1) | RU2756313C2 (enExample) |
| SG (2) | SG11201810816QA (enExample) |
| SI (1) | SI3464338T1 (enExample) |
| SM (1) | SMT202100586T1 (enExample) |
| TW (2) | TWI752036B (enExample) |
| WO (1) | WO2017214175A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3464338T (lt) | 2016-06-07 | 2022-01-10 | Modernatx, Inc. | Modifikuota rnr, koduojanti vegf-a polipeptidus, vaisto formos, ir su jomis susiję panaudojimo būdai |
| US11628227B2 (en) * | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| PL3703658T3 (pl) | 2017-10-31 | 2022-08-22 | Astrazeneca Ab | Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a |
| US20220226243A1 (en) * | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same |
| JP7345888B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| WO2023061985A2 (en) * | 2021-10-12 | 2023-04-20 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
| WO2023084013A1 (en) * | 2021-11-12 | 2023-05-19 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| EP1863516A2 (en) | 2005-02-08 | 2007-12-12 | Board of Regents, The University of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
| WO2010065601A1 (en) * | 2008-12-03 | 2010-06-10 | Amorcyte, Inc. | Infarct area perfusion-improving compositions and methods of vascular injury repair |
| CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| WO2011069529A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| WO2012103985A2 (en) | 2010-12-16 | 2012-08-09 | Steve Pascolo | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| JP2014511694A (ja) | 2011-04-03 | 2014-05-19 | ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル | 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| JP2015510495A (ja) | 2011-12-21 | 2015-04-09 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 器官または器官移植片の生存可能性または寿命を延長する方法 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US20140275229A1 (en) * | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
| US9663564B2 (en) | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| WO2014152211A1 (en) * | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| BR112016016416A2 (pt) * | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| LT3464338T (lt) | 2016-06-07 | 2022-01-10 | Modernatx, Inc. | Modifikuota rnr, koduojanti vegf-a polipeptidus, vaisto formos, ir su jomis susiję panaudojimo būdai |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| MX389934B (es) | 2016-12-09 | 2025-03-20 | Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos. |
| PL3703658T3 (pl) | 2017-10-31 | 2022-08-22 | Astrazeneca Ab | Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a |
| EP3965797A1 (en) | 2019-05-08 | 2022-03-16 | AstraZeneca AB | Compositions for skin and wounds and methods of use thereof |
-
2017
- 2017-06-06 LT LTEPPCT/US2017/036188T patent/LT3464338T/lt unknown
- 2017-06-06 KR KR1020237003204A patent/KR102552543B1/ko active Active
- 2017-06-06 PL PL17734885T patent/PL3464338T3/pl unknown
- 2017-06-06 SI SI201730935T patent/SI3464338T1/sl unknown
- 2017-06-06 US US16/305,224 patent/US11866475B2/en active Active
- 2017-06-06 MX MX2018015110A patent/MX2018015110A/es unknown
- 2017-06-06 ES ES17734885T patent/ES2895421T3/es active Active
- 2017-06-06 JP JP2018564389A patent/JP6859369B2/ja active Active
- 2017-06-06 RS RS20211280A patent/RS62556B1/sr unknown
- 2017-06-06 SG SG11201810816QA patent/SG11201810816QA/en unknown
- 2017-06-06 RU RU2018147229A patent/RU2756313C2/ru active
- 2017-06-06 HR HRP20211569TT patent/HRP20211569T1/hr unknown
- 2017-06-06 CA CA3026500A patent/CA3026500A1/en active Pending
- 2017-06-06 PT PT177348851T patent/PT3464338T/pt unknown
- 2017-06-06 SM SM20210586T patent/SMT202100586T1/it unknown
- 2017-06-06 CN CN201780048447.8A patent/CN109790207B/zh active Active
- 2017-06-06 MA MA45172A patent/MA45172B1/fr unknown
- 2017-06-06 WO PCT/US2017/036188 patent/WO2017214175A1/en not_active Ceased
- 2017-06-06 AU AU2017277277A patent/AU2017277277B2/en not_active Ceased
- 2017-06-06 EP EP21186195.0A patent/EP3971204A1/en not_active Withdrawn
- 2017-06-06 KR KR1020227008509A patent/KR102494499B1/ko active Active
- 2017-06-06 CN CN202310693718.2A patent/CN116606861A/zh active Pending
- 2017-06-06 SG SG10202012175YA patent/SG10202012175YA/en unknown
- 2017-06-06 HU HUE17734885A patent/HUE056055T2/hu unknown
- 2017-06-06 KR KR1020197000227A patent/KR102376245B1/ko active Active
- 2017-06-06 DK DK17734885.1T patent/DK3464338T3/da active
- 2017-06-06 EP EP17734885.1A patent/EP3464338B1/en active Active
- 2017-06-06 KR KR1020237022229A patent/KR20230107891A/ko not_active Ceased
- 2017-06-07 TW TW106118838A patent/TWI752036B/zh not_active IP Right Cessation
- 2017-06-07 TW TW110145699A patent/TWI818375B/zh not_active IP Right Cessation
-
2018
- 2018-11-29 IL IL263370A patent/IL263370A/en unknown
-
2021
- 2021-03-24 JP JP2021049671A patent/JP7167226B2/ja active Active
- 2021-10-14 CY CY20211100889T patent/CY1124667T1/el unknown
-
2022
- 2022-10-26 JP JP2022171389A patent/JP2023011733A/ja active Pending
-
2023
- 2023-07-28 AU AU2023208200A patent/AU2023208200A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211569T1 (hr) | Modificirana rna koja kodira vegf-a polipeptide, formulacije, i upotrebe koje se na njih odnose | |
| JP2019521976A5 (enExample) | ||
| US20070093748A1 (en) | Methods and systems for treating injured cardiac tissue | |
| US20070172472A1 (en) | Methods and Systems for Treating Injured Cardiac Tissue | |
| US20100280493A1 (en) | Methods and Systems for Treating Injured Cardiac Tissue | |
| JP2010163457A (ja) | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 | |
| JP3012319B2 (ja) | 脳及び筋肉組織傷害による浮腫の治療剤 | |
| Funatsu et al. | Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor | |
| WO2022076556A3 (en) | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 | |
| CN118121634B (zh) | IMRC-Exo在制备减轻心脏骤停复苏后多器官损伤药物中的应用及药物 | |
| JP2010270156A (ja) | 虚血性疾患の予防または治療剤 | |
| EP1142590A1 (en) | Gene therapy for diabetic ischemic disease | |
| Shimokawa et al. | Extracorporeal cardiac shock wave therapy for ischemic heart disease | |
| JP2005206544A (ja) | 筋肉再生剤 | |
| Wu et al. | Placental growth factor 2—a potential therapeutic strategy for chronic myocardial ischemia | |
| JP7630173B2 (ja) | ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物 | |
| Levy et al. | Effect of acute coronary artery ligation upon blood flow to the normal myocardium | |
| KR101418941B1 (ko) | 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물 | |
| JP2009530411A (ja) | 損傷心臓組織治療の方法と方式 | |
| WO2017188852A1 (ru) | Способ проведения кардиоплегии | |
| Neuta et al. | Evaluation of the repairing effect of collagen type I and MaxGel on the infarcted myocardium in an animal model | |
| Hirota et al. | Post-mortem tissue-type plasminogen activator preserves graft function of hearts harvested from non-pre-treated non-heart-beating donors | |
| CN103239714B (zh) | 用于治疗缺血性疾病的蛋白质及药物组合物 | |
| Berne et al. | Evaluation of procedures designed to enhance coronary collateral blood flow | |
| Chopard et al. | P3555 Non-recommended dosing of direct oral anticoagulants in acute pulmonary embolism is related to an increased rate of adverse events at 6 months: results of a prospective regional multicenter registry |